Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
How Replimune's drug got a third chance after the White House intervened
Replimune to resubmit twice-rejected drug for approval after FDA shakeup
Replimune reaches agreement with US FDA to resubmit melanoma drug application
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
Replimune Gets Third Try at FDA Approval After Makary Departure
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
Replimune: Perhaps The FDA Shakeup Will Get A Mulligan For RP1
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
What's Going On With Replimune Stock On Tuesday?
FDA Commissioner Makary defends agency's decision on Replimune's drug
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
FDA Rejection Sparks Questions On Replimune Drug Approval Path
Replimune Gets Second FDA CRL for Melanoma Drug BLA, Stock Crashes
Replimune melanoma therapy rejected by FDA, shares plunge
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
Stock Market Today (LIVE): Futures Rebound as Investors Shift Focus to Bank Earnings Despite U.S. Navy Blockade and Rising Crude
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
US FDA declines to approve Replimune's drug for advanced skin cancer
Replimune Group (NASDAQ:REPL) Insider Christopher Sarchi Sells 6,500 Shares of Stock
Replimune Group, Inc. (NASDAQ:REPL) Given Consensus Rating of “Hold” by Analysts
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
Does Replimune Group (REPL) Have the Potential to Rally 79.61% as Wall Street Analysts Expect?
Replimune to Present at Two Upcoming Investor Conferences
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
SG Americas Securities LLC Increases Stake in Replimune Group, Inc. $REPL
Replimune Group, Inc. (REPL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Squarepoint Ops LLC Grows Stock Position in Replimune Group, Inc. $REPL
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of “Moderate Buy” by Brokerages
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Why Replimune Stock Was Soaring Today
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma